Five ‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial

Cancer Science, EarlyView.

Source: Cancer Science - August 27, 2018 Category: Cancer & Oncology Authors: Yasuyoshi Morita , Yasuhiro Maeda , Terufumi Yamaguchi , Fumiaki Urase , Shuhei Kawata , Hitoshi Hanamoto , Kazuo Tsubaki , Jun Ishikawa , Hirohiko Shibayama , Itaru Matsumura , Mitsuhiro Matsuda Source Type: research